229 related articles for article (PubMed ID: 32572107)
1. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
3. T2-FLAIR Mismatch: An Imaging Biomarker for Children's
van Maren EA; Dankbaar JW; Wesseling P; Plasschaert S; Muhlebner A; Hoving EW; Robe PA; Snijders TJ; Hoogendijk R; Kranendonk MEG; Lequin MH
AJNR Am J Neuroradiol; 2024 Jun; 45(6):747-752. PubMed ID: 38724203
[TBL] [Abstract][Full Text] [Related]
4. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
[TBL] [Abstract][Full Text] [Related]
5. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.
Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM
AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098
[TBL] [Abstract][Full Text] [Related]
6. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
7. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
8. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
[TBL] [Abstract][Full Text] [Related]
9. The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
Fujita Y; Nagashima H; Tanaka K; Hashiguchi M; Hirose T; Itoh T; Sasayama T
World Neurosurg; 2021 May; 149():e253-e260. PubMed ID: 33610870
[TBL] [Abstract][Full Text] [Related]
10. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
[TBL] [Abstract][Full Text] [Related]
11. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
[TBL] [Abstract][Full Text] [Related]
12. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
[TBL] [Abstract][Full Text] [Related]
13. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
[TBL] [Abstract][Full Text] [Related]
14. T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma.
Wagner MW; Nobre L; Namdar K; Khalvati F; Tabori U; Hawkins C; Ertl-Wagner BB
AJNR Am J Neuroradiol; 2023 Jul; 44(7):841-845. PubMed ID: 37348970
[TBL] [Abstract][Full Text] [Related]
15. "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
Jain R; Johnson DR; Patel SH; Castillo M; Smits M; van den Bent MJ; Chi AS; Cahill DP
Neuro Oncol; 2020 Jul; 22(7):936-943. PubMed ID: 32064507
[TBL] [Abstract][Full Text] [Related]
16. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
Park SI; Suh CH; Guenette JP; Huang RY; Kim HS
Eur Radiol; 2021 Jul; 31(7):5289-5299. PubMed ID: 33409784
[TBL] [Abstract][Full Text] [Related]
17. Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study.
Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Hata N; Mizoguchi M; Yamamoto H; Iwaki T; Hiwatashi A; Ishigami K
Sci Rep; 2022 Jun; 12(1):9197. PubMed ID: 35654812
[TBL] [Abstract][Full Text] [Related]
18. There is an exception to every rule-T2-FLAIR mismatch sign in gliomas.
Johnson DR; Kaufmann TJ; Patel SH; Chi AS; Snuderl M; Jain R
Neuroradiology; 2019 Feb; 61(2):225-227. PubMed ID: 30565056
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
20. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]